Cleveland BioLabs, Inc. - CBLI - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Cleveland BioLabs, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
CBLI	Nasdaq	8731	http://www.cbiolabs.com	1.49 0.00
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Cleveland BioLabs, Inc. Profiting From BARDA Contract Awards - May 22nd, 2013 11:33 am Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference - May 22nd, 2013 6:00 am CLEVELAND BIOLABS INC Financials - May 17th, 2013 11:04 am 4 Healthcare Stock Stories For Tuesday Investment Wellness - May 14th, 2013 6:10 pm Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins - May 14th, 2013 5:30 am Cleveland BioLabs' CEO Discusses Q1 2013 Results - Earnings Call Transcript - May 9th, 2013 3:11 pm CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress - May 9th, 2013 7:13 am Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress - May 9th, 2013 5:30 am Q1 2013 CLEVELAND BIOLABS INC Earnings Release - Before Market Open - May 9th, 2013 5:07 am CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princ - May 8th, 2013 10:40 pm Cleveland BioLabs Announces Appointment of Shareholder Representative to Board - May 8th, 2013 5:30 am Isis Initiates ISIS-STAT3 Study - May 7th, 2013 3:16 pm Zacks Bull and Bear of the Day Highlights: Private Bancorp, Pan American Silver, AVEO Pharmaceuticals, Astellas Pharma and Cleveland BioLabs - May 6th, 2013 5:16 am Negative Opinion on AVEO/ALPMY Candidate - May 3rd, 2013 2:30 pm Loss at Aegerion Narrower Than Expected - May 3rd, 2013 2:00 pm Vertex Loss Lower, Kalydeco Outlook Up - May 1st, 2013 6:22 am Cleveland BioLabs, Roswell Park Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502) - May 1st, 2013 5:00 am Double Setback for Gilead - Apr 30th, 2013 1:20 pm Merck - Pfizer in Diabetes Deal - Apr 30th, 2013 12:30 pm Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide Operational Update on May 9 - Apr 30th, 2013 7:25 am View All Current Headlines >>